Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Cladribine Action Pathway
Homo sapiens
Drug Action Pathway
Cladribine is an antineoplastic agent with immunosuppressive effects (antimetabolite). It is used in the treatment of active hairy cell leukemia and relapsing forms of Multiple sclerosis (MS). This drug is mostly used with patients who did not respond to alternative MS drugs. It is also used as an alternative drug for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma. This molecule is a synthetic purine nucleoside, it is structurally close to deoxyadenosine. The only difference is that cladribine has a chlorine atom at position 2 of the purine ring, this makes the drug resistant to the enzymatic degradation by adenosine deaminase. Due to this resistance, this molecule has the ability to prolong its cytotoxicity. The complete mechanism of action of cladribine is still unclear, it is thought that it is phosphorylated to nucleotidecladribine triphosphate and this metabolite is incorporated into the DNA of T and B cells. This results in DNA strand breakage and inhibition of the DNA synthesis and/or repair. This drug has cytotoxic effects on resting as well as proliferating lymphocytes, which differentiates it from all the other antimetabolite drugs. The drug causes the lymphocytes to stay and accumulate in the G1/S phase. This suggests that the cell cytotoxicity is caused during critical events to enter the S phase. An overdose of this drug would result in irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia. This drug is administered as an intravenous solution or as an oral tablet.
References
Cladribine Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Warnke C, Wiendl H, Hartung HP, Stuve O, Kieseier BC: Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627.
Pubmed: 20689698
Sigal DS, Miller HJ, Schram ED, Saven A: Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010 Oct 21;116(16):2884-96. doi: 10.1182/blood-2010-02-246140. Epub 2010 Jul 15.
Pubmed: 20634380
Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.
Pubmed: 19715446
Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.
Pubmed: 19576186
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings